Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Austria; Ludwig Boltzmann Institute for Hematology & Oncology, Medical University of Vienna, Austria.
Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Austria; Ludwig Boltzmann Institute for Hematology & Oncology, Medical University of Vienna, Austria.
Semin Cancer Biol. 2020 Feb;60:191-201. doi: 10.1016/j.semcancer.2019.07.025. Epub 2019 Aug 10.
The development of a myeloid neoplasm is a step-wise process that originates from leukemic stem cells (LSC) and includes pre-leukemic stages, overt leukemia and a drug-resistant terminal phase. Organ-invasion may occur in any stage, but is usually associated with advanced disease and a poor prognosis. Sometimes, extra-medullary organ invasion shows a metastasis-like or even sarcoma-like destructive growth of neoplastic cells in local tissue sites. Examples are myeloid sarcoma, mast cell sarcoma and localized blast phase of chronic myeloid leukemia. So far, little is known about mechanisms underlying re-distribution and extramedullary dissemination of LSC in myeloid neoplasms. In this article, we discuss mechanisms through which LSC can mobilize out of the bone marrow niche, can transmigrate from the blood stream into extramedullary organs, can invade local tissue sites and can potentially create or support the formation of local stem cell niches. In addition, we discuss strategies to interfere with LSC expansion and organ invasion by targeted drug therapies.
髓系肿瘤的发展是一个逐步的过程,起源于白血病干细胞(LSC),包括前白血病阶段、显性白血病和耐药终末阶段。器官浸润可发生在任何阶段,但通常与晚期疾病和预后不良有关。有时,骨髓外器官浸润表现为局部组织部位肿瘤细胞的转移样甚至肉瘤样破坏性生长。例如髓样肉瘤、肥大细胞肉瘤和慢性髓系白血病的局限性急变期。到目前为止,人们对髓系肿瘤中 LSC 重新分布和骨髓外播散的机制知之甚少。在本文中,我们讨论了 LSC 可以从骨髓龛中动员出来、可以从血流中穿过进入骨髓外器官、可以侵犯局部组织部位以及可以潜在地形成或支持局部干细胞龛的机制。此外,我们还讨论了通过靶向药物治疗来干扰 LSC 扩增和器官浸润的策略。